In another study, treatment of NMC cell lines in vitro with NEO02734, a dual inhibitor p300 and BET has shown promise29 and is currently recruiting patients in a clinical trial for patients with NMC and prostate cancer (NCT05488548). Here, DNER is linked to nut midline carcinoma.